Eliem Therapeutics (ELYM) Competitors $1.24 -0.03 (-2.36%) As of 05/20/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ELYM vs. NLTX, EPRX, ACRS, ADCT, LRMR, EDIT, GLSI, TARA, SCPH, and LYELShould you be buying Eliem Therapeutics stock or one of its competitors? The main competitors of Eliem Therapeutics include Neoleukin Therapeutics (NLTX), Eupraxia Pharmaceuticals (EPRX), Aclaris Therapeutics (ACRS), ADC Therapeutics (ADCT), Larimar Therapeutics (LRMR), Editas Medicine (EDIT), Greenwich LifeSciences (GLSI), Protara Therapeutics (TARA), scPharmaceuticals (SCPH), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical products" industry. Eliem Therapeutics vs. Neoleukin Therapeutics Eupraxia Pharmaceuticals Aclaris Therapeutics ADC Therapeutics Larimar Therapeutics Editas Medicine Greenwich LifeSciences Protara Therapeutics scPharmaceuticals Lyell Immunopharma Neoleukin Therapeutics (NASDAQ:NLTX) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their community ranking, profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations. Which has more risk & volatility, NLTX or ELYM? Neoleukin Therapeutics has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Comparatively, Eliem Therapeutics has a beta of -0.39, suggesting that its share price is 139% less volatile than the S&P 500. Does the media favor NLTX or ELYM? In the previous week, Neoleukin Therapeutics had 1 more articles in the media than Eliem Therapeutics. MarketBeat recorded 2 mentions for Neoleukin Therapeutics and 1 mentions for Eliem Therapeutics. Neoleukin Therapeutics' average media sentiment score of 0.37 beat Eliem Therapeutics' score of -0.39 indicating that Neoleukin Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neoleukin Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eliem Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation & earnings, NLTX or ELYM? Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Eliem Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeoleukin TherapeuticsN/AN/A-$57.56M-$3.11-5.96Eliem TherapeuticsN/AN/A-$35.12M-$0.53-2.34 Do insiders & institutionals have more ownership in NLTX or ELYM? 52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by company insiders. Comparatively, 4.7% of Eliem Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is NLTX or ELYM more profitable? Neoleukin Therapeutics' return on equity of -37.22% beat Eliem Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neoleukin TherapeuticsN/A -37.22% -30.91% Eliem Therapeutics N/A -47.03%-45.97% Does the MarketBeat Community believe in NLTX or ELYM? Neoleukin Therapeutics received 41 more outperform votes than Eliem Therapeutics when rated by MarketBeat users. However, 56.25% of users gave Eliem Therapeutics an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote. CompanyUnderperformOutperformNeoleukin TherapeuticsOutperform Votes5045.87% Underperform Votes5954.13% Eliem TherapeuticsOutperform Votes956.25% Underperform Votes743.75% SummaryNeoleukin Therapeutics and Eliem Therapeutics tied by winning 6 of the 12 factors compared between the two stocks. Get Eliem Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELYM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELYM vs. The Competition Export to ExcelMetricEliem TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.89M$6.45B$5.31B$8.42BDividend YieldN/A2.64%5.21%4.10%P/E Ratio-2.349.0426.7819.69Price / SalesN/A253.23386.97118.34Price / CashN/A65.8538.2534.62Price / Book0.326.406.744.50Net Income-$35.12M$143.98M$3.23B$248.32M7 Day Performance5.98%1.90%1.49%-0.03%1 Month Performance0.81%4.01%11.47%12.72%1 Year Performance-84.24%-3.00%16.57%7.38% Eliem Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELYMEliem TherapeuticsN/A$1.24-2.4%N/A-84.2%$36.89MN/A-2.349NLTXNeoleukin TherapeuticsN/A$14.73-1.8%N/A-45.5%$138.43MN/A-4.7490Gap UpHigh Trading VolumeEPRXEupraxia Pharmaceuticals2.2038 of 5 stars$3.86+1.4%$10.50+172.4%+32.3%$138.20MN/A-5.3529Gap UpACRSAclaris Therapeutics2.8743 of 5 stars$1.25-0.8%$10.67+753.3%+9.3%$135.35M$18.72M-2.40100Positive NewsGap DownADCTADC Therapeutics2.6735 of 5 stars$1.35+5.9%$7.75+476.2%-47.6%$133.39M$70.84M-0.56310Analyst RevisionLRMRLarimar Therapeutics2.0736 of 5 stars$2.08-1.9%$19.63+843.5%-75.5%$133.18MN/A-1.8130Positive NewsGap UpEDITEditas Medicine4.2669 of 5 stars$1.54+6.2%$5.73+271.9%-72.8%$128.91M$32.31M-0.60230GLSIGreenwich LifeSciences1.2042 of 5 stars$9.58+1.6%$39.00+307.1%-28.1%$127.17MN/A-11.973Positive NewsEarnings ReportTARAProtara Therapeutics2.1908 of 5 stars$3.27+0.9%$20.40+523.9%+10.9%$126.15MN/A-1.1630Positive NewsSCPHscPharmaceuticals4.107 of 5 stars$2.48+1.6%$14.00+464.5%-12.7%$124.70M$36.33M-1.3130Analyst RevisionLYELLyell Immunopharma2.9658 of 5 stars$0.42+5.4%$1.00+137.2%-84.3%$124.52M$61,000.00-0.53270Positive News Related Companies and Tools Related Companies Neoleukin Therapeutics Alternatives Eupraxia Pharmaceuticals Alternatives Aclaris Therapeutics Alternatives ADC Therapeutics Alternatives Larimar Therapeutics Alternatives Editas Medicine Alternatives Greenwich LifeSciences Alternatives Protara Therapeutics Alternatives scPharmaceuticals Alternatives Lyell Immunopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELYM) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eliem Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eliem Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ELYM Stock Free ELYM Stock Alerts